Bristol-Myers Squibb Stock (BMY) – Plunge For A Second Day – Trade Alert and Updates – Aug 8 2016

Bristol-Myers Squibb Stock is once more under selling pressure as various brokerages have downgraded their outlook for the stock following the failure of the Opdivo trial . Credit Suisse has downgraded the stock to neutral and lowered their price target to $63 from $86. They wrote that the failure of the Opdivo trial “stunned” their analysts.

Meanwhile Goldman Sachas which had downgraded the stock back in June, place another downgrade today which is also hurting the stock further. Goldman and Credit Suisse are not the only brokerages to downgrade the stock.

Update To Bristol-Myers Squibb Stock Rescue Strategy

The second plunge today is, in my opinion, an overreaction by investors. Here is how I am handling my Bristol-Myers Squibb Stock positions along with trades done again today.

BMY Stock Trade Alert Details

FullyInformed Members can read this Bristol-Myers Squibb Stock trade alert and outline by logging in directly through this link. Members can sign in here. Non-members can join here.

Recommended Related Links:

Understanding The Bollinger Bands Strategy Trade

Other Bollinger Bands Strategy Trade Articles

How To Avoid Being Shaken Out Of A Trade

Internal Stock and Option Trades Links

Portfolio Listing by Years

My Principal Stocks Index

Trade Ideas for Members

Trade Alerts for Members

Put Selling Strategies

Put Selling Strategies For Members

Covered Calls Strategies

Covered Calls Strategies For Members

Profit And Income Strategies Index

Stock and Option Strategies For Members

Stock And Option Trades Explained For Members

Ask A Question About A Trade You Are In

Sign My Guestbook

Visit My Shop

Join The Free Options Forum